A report on Guest Lecture (6th March, 2025)

Topic: How AI is Transforming the Future of Peptide Based Medicines
Organized by:
Department of Pharmacy
Integral University, Lucknow

Dr. Ved Srivastava is a Chief Technology Officer at Perpetual Medicines. He delivered his lecture on 'How AI is Transforming the Future of Peptide Based Medicines.' He further emphasized that AI is revolutionizing the field of peptide-based medicines by enabling faster and more efficient drug discovery. He said that through advanced algorithms, AI can predict peptide structures, optimize sequences, and analyse vast amounts of biological data to identify potential therapeutic candidates. This process accelerates the development process, reducing costs and time to market.

In alignment with Program Outcomes (POs) such as PO1 (Pharmacy Knowledge), PO4 (Modern Tool Usage), and PO1 (Life-long Learning), the session highlighted the integration of technological advancements with pharmaceutical sciences. The emphasis on precision medicine also reflects PO6 (Professional Identity) and PO7 (Pharmaceutical Ethics), showcasing a responsible approach to drug development through innovation.

He further emphasized that at Perpetual Medicines, they use AI to enhance peptide stability, bioavailability, and efficacy, ensuring precision in personalized medicine. As AI continues to evolve, it holds the potential to unlock groundbreaking treatments, improving patient outcomes globally. This vision strongly supports Sustainable Development Goals (SDGs) such as SDG 3 (Good Health and Well-being), SDG 4 (Quality Education) and SDG 9 (Industry, Innovation and Infrastructure), as the session encouraged scientific advancement and learning.

The future of peptide-based therapies is brighter than ever. His motivational lecture engaged the audience with latest facts and figures in the field of pharmacy, promoting PO8 (Communication) by encouraging dialogue on cutting-edge developments in pharmaceutical research.





Lecture given by Dr. Ved Srivastava,

Expert interaction with Participants

Chief Technology Officer, Perpetual Medicines, Boston, USA

Prof Juber Akhtar

Head

Prof (Dr.) Syed Misbahul Hasan

Dean